Verge Genomics uses human data and AI to develop better drugs faster. It operates an end-to-end, technology-driven drug discovery platform that leverages proprietary patient genomics datasets and machine learning, with an 'all-in-human' approach focused on neurodegenerative and other diseases. The company was founded in 2015 by Alice Zhang (CEO) and was part of Y Combinator's Summer 2015 batch. Verge raised a $98M Series B led by funds managed by BlackRock with participation from Eli Lilly, Merck GHI, Section 32, and others.
Verge Genomics
ActiveWe use human data and AI to develop better drugs faster
Total raised
$98.5M
2 rounds
Stage
Series B
Dec 2021
Team
11-50
since 2015
Pricing
—
Founded
2015
San Francisco, United States
Agent-ready
—
AI-driven drug discovery using human genomics data
End-to-end 'all-in-human' discovery platform
Proprietary patient genomics datasets
Machine learning for target identification
Focus on neurodegenerative and other diseases
Technology-driven approach to developing medicines faster
Integration of human data across the pipeline
Platform spanning discovery to development
12/100
Early
MCP server
Public API
Webhooks
OAuth 2.0
SDKs
No public agent surfaces detected yet.
Cumulative raise
From 2015 to 2026 · 2 rounds tracked
Total
$98.5M
Dec 2021 Series B $98M ● BlackRock
Jan 2015 Seed $500K ● Y Combinator
Capital network
$98.5M raised ·10 backers·10 network links
- Backers10
- Shared portfoliocompanies these backers also fund
- Extended networkfunds that co-invest alongside them
Pearl Health
AI value-based care platform for primary care providers
AI AnalyticsAI Healthcare
Commure
AI Healthcare
Innovaccer
AI Healthcare
Truveta
AI Healthcare
Terray Therapeutics
Generative AI and ultra-high-throughput chemistry for small-molecule drug discovery
AI HealthcareDrug Discovery
Genesis Molecular AI
Generative AI for small-molecule drug discovery
AI HealthcareDrug Discovery
- What does Verge Genomics do?
- Verge Genomics uses human data and AI to develop better drugs faster, running an end-to-end, all-in-human drug discovery platform focused on neurodegenerative and other diseases.
- What makes its approach distinctive?
- Verge emphasizes an 'all-in-human' approach, using proprietary patient genomics datasets and machine learning rather than relying primarily on animal models.
- Who founded Verge Genomics?
- It was founded in 2015 by Alice Zhang (CEO) and was part of Y Combinator's Summer 2015 batch.
- How is it funded?
- Verge raised a $98M Series B led by funds managed by BlackRock, with participation from Eli Lilly, Merck GHI, Section 32, and others.
Discussion
Sign in to join the discussion.
Sign inExplore more around Verge Genomics
Contextual paths to related AI startups, deals and rankings.